Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers

Documenti analoghi

• “I’m worth saving”‐ a qualitative study of people with dementia considering treatment with lecanemab
  di: Ayush Thacker, et al.
  Pubblicazione: (2024)
• Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
  di: Pratik Bhagunde, et al.
  Pubblicazione: (2026)
• Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease
  di: Stefan J. Teipel, et al.
  Pubblicazione: (2024)
• Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results
  di: Stefan Teipel, et al.
  Pubblicazione: (2025)
• Evaluation of amyloid change as a surrogate for cognitive decline: demonstration in individual‐level data from the A4 study of solanezumab
  di: Sarah F. Ackley, et al.
  Pubblicazione: (2026)